A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
- Registration Number
- NCT01758978
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Brief Summary
The primary objective of this study is to assess the bioequivalence of two 30-mg hydrocodone bitartrate extended-release tablets and one 60-mg hydrocodone bitartrate extended-release tablet.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
- Written informed consent is obtained.
- The subject can read, speak, and write in English.
- The subject is a man or woman 18 through 45 years of age, with a body mass index (BMI) of 20.0 to 30.0 kg/m2, inclusive.
- The subject is in good health as determined by medical and psychiatric history, physical examination, ECG, serum chemistry, hematology, urinalysis, and serology.
- Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, be using an acceptable method of contraception, and agree to continued use of this method for the duration of the study and for 30 days after discontinuation of study drug. Acceptable methods of contraception include abstinence or an intrauterine device (known to have a failure rate of less than 1% per year).
- The subject has a negative alcohol test and urine drug screen (UDS).
- The subject must be willing and able to comply with study restrictions and to remain at the study center for the required duration of each study drug period during the study.
Exclusion Criteria
- The subject has any clinically significant uncontrolled medical conditions (treated or untreated).
- The subject has a clinically significant deviation from normal in ECG or physical examination findings, as determined by the investigator or the medical monitor.
- The subject has habitually consumed, within the past 2 years, more than 21 units of alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision (DSM-IV-TR, American Psychiatric Association 2000). NOTE: A unit of alcohol is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer.
- The subject is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal (GI) surgery; a history of appendectomy is allowed).
- The subject has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before the 1st dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of study drug.
- The subject has a known sensitivity or idiosyncratic reaction to hydrocodone or hydromorphone, their related compounds, or to any metabolites, or naltrexone, or any compound listed as being present in a study formulation.
- Other exclusion criteria apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment Group AB a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B). Subjects in this group will receive study drug in the following sequence: * Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference) * Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test). Treatment Group BA a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B). Subjects in this group will receive study drug in the following sequence: * Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test). * Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference).
- Primary Outcome Measures
Name Time Method Maximum observed plasma drug concentration (Cmax) Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To assess the bioequivalence between 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.
Area under the plasma drug concentration by time curve AUC 0-∞ Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To assess bioequivalence between two 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.
- Secondary Outcome Measures
Name Time Method Time to maximum observed plasma drug concentration (tmax) Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
AUC from time 0 to 72 hours after study drug administration (AUC0-72) Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
AUC from time 0 to the time of the last measurable drug concentration (AUC0-t) Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
Percentage extrapolation, 100x(AUC0-∞-AUC0-t)/AUC0-∞) Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
Apparent plasma terminal elimination rate constant (λz) and associated elimination half life (t½) Approximately 5 minutes prior to study drug administration up to 72 post study drug administration. To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
Recording of Adverse Events From ICF signing to 48-72 hours after discharge from the study center following the last administration of the hydrocodone bitartrate extended-release tablet. To characterize the safety of the hydrocodone bitartrate extended-release tablet in healthy naltrexone-blocked subjects.
Trial Locations
- Locations (1)
Teva Investigational Site 10471
🇺🇸Austin, Texas, United States
Teva Investigational Site 10471🇺🇸Austin, Texas, United States